← 返回

GNPNAT1 调控:NSCLC 放射免疫功能与 NK 细胞抵抗中的关键作用

英文原题:GNPNAT1 Regulation: A Key Role in Radioimmune Function and NK Cell Resistance in NSCLC.

查看英文原题

GNPNAT1 Regulation: A Key Role in Radioimmune Function and NK Cell Resistance in NSCLC.

PubMed 2025/02/01(内容时间) Discov Med Q2 · IF 3.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

GNPNAT1 表达下调降低非小细胞肺癌对放疗的免疫抵抗并增强对 NK 细胞细胞毒作用的敏感性。

研究思路结论见上方概要

葡萄糖胺-6-磷酸N-乙酰转移酶1(GNPNAT1)是己糖胺生物合成途径中的一种酶,该途径对糖基化过程至关重要。在非小细胞肺癌(NSCLC)中,GNPNAT1在调节免疫反应中发挥重要作用。本研究的目的是探讨GNPNAT1在调节NSCLC患者放疗疗效及自然杀伤(NK)细胞介导的细胞毒性抵抗中的作用。

为评估GNPNAT1对放疗疗效的影响,将122例肺癌患者分为放疗敏感组和放疗抵抗组。采用qRT-PCR和Western blotting检测两组癌组织中GNPNAT1的表达水平。使用相同的分子技术将分析扩展至多种肺癌细胞系(BEAS-2B、A549、LTEP-2、SPCA1和H157)。为探究GNPNAT1在放疗抵抗中的功能作用,建立放疗抵抗A549细胞(A549R26-1),并对GNPNAT1表达进行基因操作。实验组包括对照组、si-NC、si-GNPNAT1、Oe-NC和Oe-GNPNAT1。处理后,通过qRT-PCR和Western blotting检测GNPNAT1水平。将细胞暴露于不同剂量的辐射,随后进行评估,包括细胞增殖(CCK-8实验)、放疗敏感性(平板克隆实验)和凋亡率(流式细胞术)。将分离纯化的原代NK细胞与各实验组的肺癌细胞共培养。通过乳酸脱氢酶(LDH)释放和集落形成实验评估NK细胞对肺癌细胞的细胞毒性。

与放射敏感组相比,放射抵抗组GNPNAT1表达水平显著升高(p < 0.05)。放射抵抗细胞系A549R26-1较其亲本细胞系A549P表现出更高的增殖能力和更低的凋亡水平。随后,下调A549R26-1细胞中GNPNAT1表达导致增殖减少、凋亡增加,并削弱了对NK细胞细胞毒性的抵抗能力。相反,与NK细胞共培养后上调A549R26-1细胞中GNPNAT1表达,导致增殖和存活率增加,并增强了对NK细胞细胞毒性的抵抗能力。值得注意的是,敲低GNPNAT1有效减弱了A549R26-1细胞的放射抵抗性。

展开英文摘要原文

Glucosamine-6-phosphate N-acetyltransferase 1 (GNPNAT1) is an enzyme involved in the hexosamine biosynthetic pathway, which is critical for glycosylation processes. In the context of non-small cell lung cancer (NSCLC), GNPNAT1 plays a significant role in modulating immune responses. The purpose of this study is to investigate the role of GNPNAT1 in regulating the efficacy of radiotherapy and resistance to natural killer (NK) cell-mediated cytotoxicity in patients with NSCLC.

To assess GNPNAT1's impact on radiotherapy efficacy, 122 lung cancer patients were categorized into radiosensitive and radioresistant groups. GNPNAT1 expression levels in cancerous tissues from both groups were measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting. This analysis was extended to various lung cancer cell lines (BEAS-2B, A549, LTEP-2, SPCA1, and H157) using the same molecular techniques. To investigate GNPNAT1's functional role in radioresistance, radioresistant A549 cells (A549R26-1) were established, and GNPNAT1 expression was genetically manipulated. Experimental groups included control, si-NC, si-GNPNAT1, Oe-NC, and Oe-GNPNAT1. Post-treatment, GNPNAT1 levels were measured via qRT-PCR and Western blotting. Cells were exposed to varying doses of radiation, and subsequent assessments included cell proliferation (Cell Counting Kit-8 (CCK-8) assay), radiosensitivity (plate cloning assays), and apoptosis rates (flow cytometry). Isolated and purified primary NK cells were co-cultured with lung cancer cells from each experimental group. The cytotoxicity of NK cells against lung cancer cells was assessed through lactate dehydrogenase (LDH) release and colony formation assays.

Compared to the radiosensitive group, the radioresistant group exhibited significantly elevated GNPNAT1 expression levels ( p < 0.05). The radioresistant cell line A549R26-1 demonstrated higher proliferation ability and lower apoptosis levels compared to its parental cell line, A549P. Subsequently, down-regulation of GNPNAT1 expression in A549R26-1 cells resulted in reduced proliferation, increased apoptosis, and weakened resistance to NK cell cytotoxicity. Conversely, up-regulation of GNPNAT1 expression in A549R26-1 cells following co-culture with NK cells led to increased proliferation and survival rates, and enhanced resistance to NK cell cytotoxicity. Notably, GNPNAT1 knockdown effectively attenuated the radioresistance of A549R26-1 cells.

Down-regulation of GNPNAT1 expression reduces the immune resistance of non-small cell lung cancer to radiotherapy and enhances susceptibility to NK cell cytotoxicity.

论文信息

作者
Xiang F、Dai Y、Yao C、Li Y、Zhao W、Wei J
单位
Department of Oncology, The Affiliated Chuzhou Hospital of Anhui Medical University (The First People's Hospital of Chuzhou), 239000 Chuzhou, Anhui, China.China
期刊
Discovery medicine2025 Feb
原文标识
PubMed 39973555 · DOI 10.24976/Discov.Med.202537193.26